Dianthus Therapeutics initiates Phase 2 trial for Claseprubart in multifocal motor neuropathy
Dianthus Therapeutics is conducting Phase 2 clinical trial to assess Claseprubart's safety and efficacy in adults with multifocal motor neuropathy.
Company
Pharmaceutical intelligence for Dianthus Therapeutics with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.